대한핵의학회지 (1967년~2009년)
Nucl Med Mol Imaging 2006;40(1)16~22
자궁의 악성 혼합성 뮬러리안 종양 환자에서의 FDG PET의 역할
(The Role of F-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Malignant Mixed Mullerian Tumors of the Uterus)
Author 바수키1,4,천기정1,채민정,김문홍2,김민석3,최창운1,임상무1,
Basuki Hidayat, M.D.1,4, Gi Jeong Cheon, M.D.1*, Min Jeong Chae, M.D.1, Moon Hong Kim, M.D.2, Min Suk Kim M.D.3, Chang Woon Choi, M.D.1, and Sang Moo Lim, M.D.1
Affiliation 원자력의학원 핵의학과1, 산부인과2, 해부병리과3, 하산 사디킨병원 핵의학과4
1Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea; 2Departement of Obstetric & Gynecology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences,
Abstract

Purpose: Malignant Mixed Mullerian Tumor (MMMT) of the uterine corpus is one of the very uncommon and the most lethal tumors in the uterus. The aim of this study was to evaluate the role of FDG PET in detecting distant metastasis and residual and/or recurrent disease. Methods: Ten patients who underwent FDG PET for detecting distant metastasis and recurrence were included. Focal FDG accumulation was regarded as abnormal. We also reviewed serum CA 125 levels, anatomical images, and histopathological examination. Results: Three patients of 10 FDG PET showed abnormal FDG uptake. One had high serum CA 125 levels and high fractions of carcinomatous element on histopathologic examination. FDG PET showed metastatic lesions in unexpected locations, which could not be detected by anatomical images. Another had normal serum CA 125 levels with high sarcomatous element and CT could only detect a few lesions. The other had high serum CA 125 levels and also had high carcinomatous element. Seven patients who had no abnormal uptake on FDG PET had no clinical evidence of recurrence during the follow up period (51.7¡¾12.2 months). The mean disease free intervals of these 7 patients were 36.4¡¾6.0 months. Two patients with abnormal findings had never become disease-free condition during the follow up period (6.0¡¾4.2 months. Conclusion: FDG PET could be a useful modality for unexpected distant metastasis and follow up tool in patients with MMMT. (Nucl Med Mol Imaging 2006;40(1):16-22)

Keyword FDG-PET, malignant mixed Mullerian tumors
Full text Article 40010216.pdf 40010216.pdf
(03121)서울시 종로구 지봉로 29 금호팔레스빌딩 1705호
TEL : 02-745-2040 FAX : 02-745-3833 E-mail : ksnm@ksnm.or.kr
Copyright 2012 by The Korean Society of Nuclear Medicine(KSNM)